<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Xanthorrhizol has antioxidant, anti-inflammatory, antitumoral, hepatoprotective, neuroprotective, nephroprotective, estrogenic, and antibacterial properties [
 <xref rid="B273-nutrients-10-01196" ref-type="bibr" class="xref">273</xref>,
 <xref rid="B274-nutrients-10-01196" ref-type="bibr" class="xref">274</xref>]. Pretreatment with xanthorrhizol (p.o., 200 mg/kg/day for 4 days), significantly reduced the cisplatin-induced nephrotoxicity in mice [
 <xref rid="B273-nutrients-10-01196" ref-type="bibr" class="xref">273</xref>]. Xanthorrhizol showed cancer chemopreventive action via potently inhibiting both COX-2 (IC
 <sub class="sub">50</sub> = 0.2 µg/mL) and iNOS (IC
 <sub class="sub">50</sub> = 1.0 µg/mL) [
 <xref rid="B249-nutrients-10-01196" ref-type="bibr" class="xref">249</xref>]. Xanthorrhizol was antiproliferative to MCF-7 (EC
 <sub class="sub">50</sub> = 1.71 µg/mL) and HepG2 cells (IC
 <sub class="sub">50</sub> = 4.17 µg/mL) through inducing apoptosis [
 <xref rid="B274-nutrients-10-01196" ref-type="bibr" class="xref">274</xref>]. Xanthorrhizol (at 50 mg/kg) was active against sarcoma 180 ascites in mice [
 <xref rid="B248-nutrients-10-01196" ref-type="bibr" class="xref">248</xref>]. Intraperitoneal administration of xanthorrhizol (0.1, 0.2, 0.5, and 1.0 mg/kg for 2 weeks) inhibited the formation of lung-tumor nodules in mice by 36%, 63%, 61%, and 52%, respectively [
 <xref rid="B275-nutrients-10-01196" ref-type="bibr" class="xref">275</xref>]. Xanthorrhizol strongly inhibited copper-mediated oxidation of human LDL (IC
 <sub class="sub">50</sub>= 0.4 ± 0.1 µg/mL) [
 <xref rid="B71-nutrients-10-01196" ref-type="bibr" class="xref">71</xref>]. Although the toxicological properties have not been thoroughly investigated, xanthorrhizol may cause skin or eye irritation and may damage fertility or the unborn fetus (H360) [
 <xref rid="B301-nutrients-10-01196" ref-type="bibr" class="xref">301</xref>].
</p>
